IL166588A0 - Containing disorazoles and derivatives thereof forthe treatment of benign and malignant tumoral dis eases - Google Patents
Containing disorazoles and derivatives thereof forthe treatment of benign and malignant tumoral dis easesInfo
- Publication number
- IL166588A0 IL166588A0 IL16658805A IL16658805A IL166588A0 IL 166588 A0 IL166588 A0 IL 166588A0 IL 16658805 A IL16658805 A IL 16658805A IL 16658805 A IL16658805 A IL 16658805A IL 166588 A0 IL166588 A0 IL 166588A0
- Authority
- IL
- Israel
- Prior art keywords
- disorazoles
- benign
- derivatives
- forthe treatment
- dis eases
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229930187817 disorazole Natural products 0.000 title 1
- 230000003211 malignant effect Effects 0.000 title 1
- 230000001173 tumoral effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40559402P | 2002-08-24 | 2002-08-24 | |
| PCT/EP2003/009329 WO2004024149A1 (de) | 2002-08-24 | 2003-08-22 | Arzneimittel enthaltend disorale und ihre derivate und deren anwendung zur behandlung gutartiger und bosärtiger tumorerkrankungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL166588A0 true IL166588A0 (en) | 2006-01-15 |
Family
ID=31993935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16658805A IL166588A0 (en) | 2002-08-24 | 2005-01-31 | Containing disorazoles and derivatives thereof forthe treatment of benign and malignant tumoral dis eases |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20040106662A1 (https=) |
| EP (1) | EP1536789A1 (https=) |
| JP (1) | JP2006500398A (https=) |
| KR (1) | KR20050038632A (https=) |
| CN (1) | CN1678310A (https=) |
| AR (1) | AR042617A1 (https=) |
| AU (1) | AU2003296872B2 (https=) |
| BR (1) | BR0313789A (https=) |
| CA (1) | CA2438001A1 (https=) |
| HR (1) | HRP20050277A2 (https=) |
| IL (1) | IL166588A0 (https=) |
| MX (1) | MXPA05002157A (https=) |
| NO (1) | NO20051444L (https=) |
| NZ (1) | NZ538926A (https=) |
| PL (1) | PL376407A1 (https=) |
| RU (1) | RU2322236C2 (https=) |
| TW (1) | TW200404537A (https=) |
| UA (1) | UA79480C2 (https=) |
| WO (1) | WO2004024149A1 (https=) |
| ZA (1) | ZA200501196B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101578287B (zh) * | 2006-09-06 | 2012-09-05 | 阿特纳赞塔里斯有限公司 | 地索拉唑及其衍生物与细胞结合分子的轭合物，新的地索拉唑衍生物，其制备方法及其应用 |
| JP5340155B2 (ja) * | 2006-09-06 | 2013-11-13 | エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 細胞結合分子を有するジソラゾールのコンジュゲート及びそれらの誘導体、新規ジソラゾール誘導体、それらの製法ならびに使用 |
| EP1900742A1 (en) * | 2006-09-07 | 2008-03-19 | AEterna Zentaris GmbH | Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof |
| EP3641891A4 (en) | 2017-06-22 | 2021-01-27 | William Marsh Rice University | SYNTHESIS OF DISORAZOLES AND THEIR ANALOGUES AS POWERFUL ANTI-CANCER AGENTS |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19605024A1 (de) * | 1996-01-31 | 1997-08-07 | Schering Ag | Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
| PT1412332E (pt) * | 2001-07-31 | 2005-06-30 | Jerome P Horwitz | Derivados de quinolina e sua utilizacao como agentes antitumorais |
| UA79293C2 (en) * | 2002-07-03 | 2007-06-11 | Univ Wayne State | 4-(7'-halo-2-quino (xa-) linyloxy)phenoxy propionic acid derivatives as antineoplastic agents |
| US7364877B2 (en) * | 2002-12-06 | 2008-04-29 | Kosan Biosciences, Inc. | Polynucleotides encoding disorazole polyketide synthase polypeptides |
-
2003
- 2003-08-22 EP EP03794920A patent/EP1536789A1/de not_active Withdrawn
- 2003-08-22 TW TW092123217A patent/TW200404537A/zh unknown
- 2003-08-22 MX MXPA05002157A patent/MXPA05002157A/es active IP Right Grant
- 2003-08-22 PL PL03376407A patent/PL376407A1/xx not_active Application Discontinuation
- 2003-08-22 US US10/646,904 patent/US20040106662A1/en not_active Abandoned
- 2003-08-22 KR KR1020057003109A patent/KR20050038632A/ko not_active Ceased
- 2003-08-22 JP JP2004535140A patent/JP2006500398A/ja not_active Withdrawn
- 2003-08-22 NZ NZ538926A patent/NZ538926A/xx unknown
- 2003-08-22 RU RU2005108570/15A patent/RU2322236C2/ru not_active IP Right Cessation
- 2003-08-22 CA CA002438001A patent/CA2438001A1/en not_active Abandoned
- 2003-08-22 BR BR0313789-9A patent/BR0313789A/pt not_active IP Right Cessation
- 2003-08-22 AU AU2003296872A patent/AU2003296872B2/en not_active Ceased
- 2003-08-22 UA UAA200501355A patent/UA79480C2/uk unknown
- 2003-08-22 WO PCT/EP2003/009329 patent/WO2004024149A1/de not_active Ceased
- 2003-08-22 CN CNA038200937A patent/CN1678310A/zh active Pending
- 2003-08-22 AR ARP030103050A patent/AR042617A1/es unknown
- 2003-08-22 HR HR20050277A patent/HRP20050277A2/hr not_active Application Discontinuation
-
2005
- 2005-01-31 IL IL16658805A patent/IL166588A0/xx unknown
- 2005-02-10 ZA ZA2005/01196A patent/ZA200501196B/en unknown
- 2005-03-18 NO NO20051444A patent/NO20051444L/no not_active Application Discontinuation
-
2009
- 2009-04-07 US US12/263,981 patent/US20090311264A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20050277A2 (en) | 2005-04-30 |
| BR0313789A (pt) | 2005-07-05 |
| UA79480C2 (en) | 2007-06-25 |
| CN1678310A (zh) | 2005-10-05 |
| US20090311264A1 (en) | 2009-12-17 |
| CA2438001A1 (en) | 2004-02-24 |
| MXPA05002157A (es) | 2005-05-23 |
| WO2004024149A1 (de) | 2004-03-25 |
| EP1536789A1 (de) | 2005-06-08 |
| US20040106662A1 (en) | 2004-06-03 |
| RU2005108570A (ru) | 2005-08-27 |
| AR042617A1 (es) | 2005-06-29 |
| NO20051444L (no) | 2005-05-19 |
| JP2006500398A (ja) | 2006-01-05 |
| KR20050038632A (ko) | 2005-04-27 |
| PL376407A1 (en) | 2005-12-27 |
| AU2003296872B2 (en) | 2008-02-14 |
| RU2322236C2 (ru) | 2008-04-20 |
| NZ538926A (en) | 2006-03-31 |
| TW200404537A (en) | 2004-04-01 |
| AU2003296872A1 (en) | 2004-04-30 |
| ZA200501196B (en) | 2005-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003900747A0 (en) | Diagnosis and treatment of pancreatic cancer | |
| AU6147401A (en) | Compositions and methods for the treatment of cancer | |
| AU4838600A (en) | Enhanced survival of cancer patients treated with erythropoietin and antitumor agents | |
| AU2002341566A1 (en) | Treatment and prevention of mucositis in cancer patients | |
| AU2001252945A1 (en) | Compositions and methods for therapy and diagnosis of colon cancer | |
| AU2002246519A8 (en) | Compositions and methods for the therapy and diagnosis of colon cancer | |
| AU2002339439A1 (en) | Use of heparin-binding domain of fibronectin for diagnosis and treatment of cancer | |
| EP1463495A4 (en) | AGENTS AND METHODS FOR TREATING CANCER | |
| IL158206A0 (en) | Compositions and methods for the prevention and treatment of human prostate cancer | |
| IL145397A0 (en) | Compositions and methods for treatment of cancer | |
| AU2003247784A8 (en) | Compositions and methods for treatment and detection of multiple cancers | |
| AU2001243349A1 (en) | Methods for the diagnosis and treatment of breast cancer | |
| PL368035A1 (en) | Compositions and methods for the treatment of cancer | |
| IL166588A0 (en) | Containing disorazoles and derivatives thereof forthe treatment of benign and malignant tumoral dis eases | |
| AU2002327639A1 (en) | Detection and treatment of cancers of breast | |
| AU9402401A (en) | Treatment of cancers | |
| AU2002366195A8 (en) | Use of bisindolmaleimide and gemcitabine for the treatment of cancer | |
| PT1680405E (pt) | Derivados de bengamida e sua utilização para o tratamento de doenças cancerosas | |
| AU2292801A (en) | Compositions and methods for treatment of breast cancer | |
| AU2002251286A1 (en) | Diagnosis and treatment of cancer:ii | |
| GB0115943D0 (en) | Treatment and diagosis of cancer | |
| AU8466601A (en) | Methods of screening novel agents for use in cancer therapy and prevention | |
| WO2004005463A9 (en) | Tumor antigens bfa4 and bcy1 for prevention and/or treatment of cancer | |
| AU2002322626A1 (en) | Cancer chemopreventative compounds and compositions and methods of treating cancers | |
| AU2002358905A1 (en) | Diagnosis and treatment of cancer |